3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Chordoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Solid Malignancies
1
Advanced Rare Malignant Solid Neoplasm
1
Interventions
durvalumab
18
Bevacizumab
17
atezolizumab
13
lenvatinib
10
Magnetic Resonance Spectroscopy
10
tremelimumab
8
Nivolumab
8
pembrolizumab
7
Sorafenib
6
Specimen Handling
5
camrelizumab
4
cabozantinib
4
Immunoglobulin G
4
Disulfides
4
sintilimab
3
apatinib
3
X-Rays
3
Radiotherapy
3
Radiofrequency Ablation
3
Radiation
3
Hepatectomy
3
E-7386
3
Doxorubicin
3
Cyclophosphamide
3
tislelizumab
2
relatlimab
2
dostarlimab
2
budigalimab
2
Standard of Care
2
Simvastatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Hepatocellular
×
Tiragolumab
×
Clear all
NCT05904886
2025-12-31
SKYSCRAPER-14
Hoffmann-La Roche
Phase 3
Active not recruiting
687 enrolled